Omnicell, Inc.
Financials
Valuation Metrics
Omnicell, Inc.'s Market Cap is $1.67B. At end of 2025 it was $2.04B. Ranked #2113 of 3,116 in US market (top 68%), #818 of 1,472 on NASDAQ (top 56%), #134 of 203 in Health Care Equipment & Services (top 66%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.67B | US#2,113/3,116 Sec#134/203 |
| Revenue | $1.25B | US#1,738/3,116 Sec#108/203 |
| Net Income | $39M | US#1,955/3,116 Sec#99/203 |
| Total Assets | $2.00B | US#2,076/3,116 Sec#105/203 |
| Net Assets | $1.29B | US#1,582/3,116 Sec#86/203 |
| Employees | 3,580 | US#1,396/3,116 Sec#99/203 |
| Value | ||
| P/E | 42.72x | US#1,828/3,116 Sec#88/203 |
| P/B | 1.29x | US#701/3,116 Sec#26/203 |
| PEG | 0.62x | US#675/3,116 Sec#29/203 |
| P/S | 1.34x | US#936/3,116 Sec#60/203 |
| EV/EBITDA | 14.87x | US#1,483/3,116 Sec#55/203 |
| FCF Yield | 8.47% | US#755/3,116 Sec#26/203 |
| Profitability | ||
| ROE | 3.03% | US#1,951/3,116 Sec#103/203 |
| ROA | 1.96% | US#1,648/3,116 Sec#102/203 |
| Op. Margin | 4.73% | US#1,986/3,116 Sec#108/203 |
| Revenue Growth | 8.45% | US#1,400/3,116 Sec#99/203 |
| Earnings Growth | 69.28% | US#378/3,116 Sec#16/203 |
| Financial Health | ||
| Debt Ratio | 54.76% | US#626/3,116 Sec#70/203 |
| Total Debt | $200M | US#2,237/3,116 Sec#124/203 |
| FCF | $141M | US#1,572/3,116 Sec#93/203 |
| Cash | $292M | US#1,434/3,116 Sec#83/203 |
| Current Ratio | 1.64x | US#1,506/3,116 Sec#135/203 |
| Net Debt/EBITDA | -0.87x | US#312/3,116 Sec#26/203 |
| Performance | ||
| 1Y Return | 9.32% | US#1,043/3,116 Sec#89/203 |
| 1M Return | 7.81% | US#973/3,116 Sec#99/203 |
| From 52W High | -33.25% | US#2,134/3,116 Sec#161/203 |
| 1Y MDD | -37.28% | US#1,777/3,116 Sec#110/203 |
| Trading | ||
| Volume | 620,864 shares | US#1,637/3,116 Sec#107/203 |
| Trading Value | $23M | US#1,619/3,116 Sec#114/203 |
| Per Share | ||
| EPS | $0.86 | US#1,709/3,116 Sec#93/203 |
| BPS | $28.40 | US#932/3,116 Sec#54/203 |
Company Info
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.